Siremadlin + PAZOPANIB for sarcoma

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 1 trial. Early trial in people, checking safety. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 6 Jan 2022: Trial registered, NCT05180695
  2. 15 Apr 2022: Trial started, NCT05180695

The trials

NCT05180695: HDM201 and Pazopanib in Patients With P53 Wild-type Advanced/Metastatic Soft Tissue Sarcomas

State
Under way
Phase
Phase 1 and Phase 2
People
47 taking part
Started
15 Apr 2022
Primary completion
Feb 2027
Arms
extension part : Soft-tissue sarcomas with MDM2 amplification, extension part : Soft-tissue sarcomas with no MDM2 amplification
Results
None posted
  1. 6 Jan 2022: Trial registered
  2. 15 Apr 2022: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 1 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.